Dokument: Assessment of precision medicine potential in diabetes mellitus: A meta‐regression analysis of dose‐dependent glycaemic control data from 44 randomised controlled trials
| Titel: | Assessment of precision medicine potential in diabetes mellitus: A meta‐regression analysis of dose‐dependent glycaemic control data from 44 randomised controlled trials | |||||||
| URL für Lesezeichen: | https://docserv.uni-duesseldorf.de/servlets/DocumentServlet?id=73142 | |||||||
| URN (NBN): | urn:nbn:de:hbz:061-20260430-141332-6 | |||||||
| Kollektion: | Publikationen | |||||||
| Sprache: | Englisch | |||||||
| Dokumententyp: | Wissenschaftliche Texte » Artikel, Aufsatz | |||||||
| Medientyp: | Text | |||||||
| Autoren: | Vargas, Kris G. [Autor] Siemes, Benedikt [Autor] Rütten, Tobias [Autor] Brockmeyer, Maximilian [Autor] Wolff, Georg [Autor] Kuß, Oliver [Autor] Huber, Kurt [Autor] | |||||||
| Dateien: |
| |||||||
| Stichwörter: | precision medicine , HbA1c , meta-regression analysis | |||||||
| Beschreibung: | A growing body of evidence reveals opportunities as well as challenges
for precision medicine in the prevention, diagnosis and treatment of diabetes mellitus.1,2 Indeed, the heterogeneous and multifactorial nature of diabetes may favour a more patient-centred approach. However, before additional significant efforts in precision diabetology are made, the potential of this approach with respect to precision treatment must be confirmed. In particular, it must be shown that the precision approach offers clinical benefits for the single individual with diabetes, when compared to standard care. Two conditions must be fulfilled for precision treatment to have a meaningful clinical effect3: First and foremost, heterogeneity in an individual's response to pharmacological treatment must be demonstrated. This is only possible with specialised trial designs (e.g., replicate crossover trials), which are not yet available in diabetology.4 As an alternative, results from parallel-group placebo-controlled trials can be used to evaluate the degree of treatment heterogeneity as measured by treatment response. Beyond variation within and among study participants, a larger variability in clinical outcomes would be expected in the active treatment groups compared to those allocated to placebo. Second, and if treatment heterogeneity exists, clinical predictors such as age, sex, or baseline HbA1c must be available to predict the best treatment for a single individual. By applying these concepts, we have previously embarked on assessing the clinical benefit of current pharmacological treatment in type 2 diabetes with regard to improvement in glycaemic control, body weight reduction, and all-cause mortality.5–7 The work presented here supplements those previous analyses by looking at the dose-dependent variability of HbA1c. If heterogeneity in treatment response exists, then we would expect this heterogeneity to be larger with higher doses. | |||||||
| Rechtliche Vermerke: | Originalveröffentlichung:
Vargas, K. G., Siemes, B., Rütten, T., Brockmeyer, M., Huber, K., Wolff, G., & Kuß, O. (2025). Assessment of precision medicine potential in diabetes mellitus: A meta‐regression analysis of dose‐dependent glycaemic control data from 44 randomised controlled trials. Diabetes, Obesity & Metabolism, 27(11), 6794–6797. https://doi.org/10.1111/dom.70066 | |||||||
| Lizenz: |  Dieses Werk ist lizenziert unter einer Creative Commons Namensnennung 4.0 International Lizenz | |||||||
| Fachbereich / Einrichtung: | Medizinische Fakultät | |||||||
| Dokument erstellt am: | 30.04.2026 | |||||||
| Dateien geändert am: | 30.04.2026 |
